<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896911429296</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896911429296</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Depolarized MUC1 Expression Is Closely Associated With Hypoxic Markers and Poor Outcome in Resected Non–Small Cell Lung Cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kaira</surname><given-names>Kyoichi</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nakagawa</surname><given-names>Kazuo</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ohde</surname><given-names>Yasuhisa</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Okumura</surname><given-names>Takehiro</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Takahashi</surname><given-names>Toshiaki</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Murakami</surname><given-names>Haruyasu</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Endo</surname><given-names>Masahiro</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kondo</surname><given-names>Haruhiko</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nakajima</surname><given-names>Takashi</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamamoto</surname><given-names>Nobuyuki</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911429296">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896911429296"><label>1</label>Shizuoka Cancer Center, Shizuoka, Japan</aff>
<author-notes>
<corresp id="corresp1-1066896911429296">Kyoichi Kaira, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan Email: <email>kkaira1970@yahoo.co.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>223</fpage>
<lpage>232</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>MUC1 is transmembrane mucin aberrantly overexpressed in various cancers. However, little is known about how MUC1 expression is associated with hypoxia, glucose metabolism, and epidermal growth factor receptor (EGFR) pathway, which are related to cancer progression. The aim of this study is to evaluate the relationship between MUC1 expression and these molecular markers in lung cancer. Of all 126 patients, high-grade polarized expression (HP), low-grade polarized expression (LP), and depolarized expression (DP) group were 50 (39.7%), 35 (27.8%), and 41 (32.5%), respectively. Depolarized MUC1 expression was significantly associated with poor outcome and was closely correlated with glucose metabolism (Glut1), hypoxia (HIF-1α), angiogenesis (vascular endothelial growth factor and microvessel density), amino acid metabolism (LAT1), and EGFR expression. High-grade polarized MUC1 expression was associated with favorable prognosis and adenocarcinoma. Depolarized MUC1 expression was significantly associated with poor outcome. Glucose metabolism, hypoxia, angiogenesis, amino acid metabolism, and EGFR pathway may play an important role in the development of depolarized MUC1 expression.</p>
</abstract>
<kwd-group>
<kwd>MUC1</kwd>
<kwd>NSCLC</kwd>
<kwd>prognosis</kwd>
<kwd>hypoxia</kwd>
<kwd>EGFR</kwd>
<kwd>Glut1</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896911429296" sec-type="intro">
<title>Introduction</title>
<p>MUC1 is a transmembrane mucin consisting of a heavily <italic>O</italic>-glycosylated extracellular domain, a transmembrane domain, and a cytoplasmic tail of 72 amino acids.<sup><xref ref-type="bibr" rid="bibr1-1066896911429296">1</xref></sup> MUC1 oncoprotein has been documented to be aberrantly expressed at high levels in most human neoplasms and plays important roles in development and progression of malignant tumors.<sup><xref ref-type="bibr" rid="bibr2-1066896911429296">2</xref><xref ref-type="bibr" rid="bibr3-1066896911429296"/>-<xref ref-type="bibr" rid="bibr4-1066896911429296">4</xref></sup> Moreover, MUC1 has emerged as a target molecule in immunotherapy for various cancers. As the mechanism of a target for cancer treatment, unmasked epitopes of MUC1 core protein expressed on tumor cells have been described to be able to elicit a strong antitumor immunity.<sup><xref ref-type="bibr" rid="bibr4-1066896911429296">4</xref></sup> Several researchers described that MUC1 expression is correlated with poor outcome in various human neoplasms.<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref>,<xref ref-type="bibr" rid="bibr5-1066896911429296">5</xref></sup></p>
<p>Non–small cell lung cancer (NSCLC) is the leading cause of cancer death and has a dismal prognosis. To improve the outcome of NSCLC patients, the biomarkers that may predict the prognosis and response to the specific therapy should be established. Tumor staging and performance status have been consistently shown to be the most powerful prognostic tool for predicting the outcome of NSCLC patients.<sup><xref ref-type="bibr" rid="bibr6-1066896911429296">6</xref></sup> However, there has been no established clinical marker, which correlates with the response to the treatment and the prognosis, in patients with NSCLC.</p>
<p>Recently, several reports have documented that the overexpression of MUC1 has a crucial role on the cancer progression and metastasis, leading to poor outcome, in patients with NSCLC.<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref>,<xref ref-type="bibr" rid="bibr5-1066896911429296">5</xref>,<xref ref-type="bibr" rid="bibr7-1066896911429296">7</xref><xref ref-type="bibr" rid="bibr8-1066896911429296"/><xref ref-type="bibr" rid="bibr9-1066896911429296"/>-<xref ref-type="bibr" rid="bibr10-1066896911429296">10</xref></sup> Giatromanolaki et al<sup><xref ref-type="bibr" rid="bibr9-1066896911429296">9</xref></sup> described that MUC1 expression was significantly correlated with vascular endothelial growth factor (VEGF) expression and was found in highly vascularized NSCLC tumors. One in vitro study suggests that hypoxia enhances MUC1 expression through the transcriptional regulation by hypoxia-inducible factor-1 alpha (HIF-1α) in lung adenocarcinoma (AC) cell line.<sup><xref ref-type="bibr" rid="bibr11-1066896911429296">11</xref></sup> HIF-1α is considered to support tumor growth by the induction of angiogenesis via the expression of the VEGF and also by high and anaerobic metabolic mechanisms.<sup><xref ref-type="bibr" rid="bibr12-1066896911429296">12</xref></sup> Glucose transporter-1 (Glut1) is thought to be a possible intrinsic marker of hypoxia, and the expression of Glut1 has been found to be regulated by hypoxia in a HIF-1-dependent way.<sup><xref ref-type="bibr" rid="bibr13-1066896911429296">13</xref>,<xref ref-type="bibr" rid="bibr14-1066896911429296">14</xref></sup> In addition, mammalian target of rapamycin (mTOR) is a downstream component of the PI3K/Akt pathway involved in the regulation of cell proliferation, angiogenesis, and metabolism. Epidermal growth factor receptor (EGFR) is an upstream component of the PI3K/Akt/mTOR signaling pathway in human neoplasms and is overexpressed in many cancers. Hisatsune et al<sup><xref ref-type="bibr" rid="bibr15-1066896911429296">15</xref></sup> reported that anti-MUC1 antibody inhibits EGFR signaling in cancer cell, and MUC1 is closely associated with EGFR expression. One in vitro study demonstrated that expression of MUC1 activates the PI3K/Akt pathway.<sup><xref ref-type="bibr" rid="bibr16-1066896911429296">16</xref></sup> However, little is known about how MUC1 expression is associated with EGFR expression, Akt/mTOR signaling pathway, and hypoxic markers in human neoplasms. As many factors can influence the extent of MUC1 expression, the underlying mechanisms for the overexpression of MUC1 are still a matter of debate in patients with NSCLC. In patients with NSCLC, hypoxia, angiogenesis, glucose metabolism, amino acid metabolism, and EGFR pathway are closely associated with tumor progression, metastasis, and prognosis.<sup><xref ref-type="bibr" rid="bibr17-1066896911429296">17</xref>,<xref ref-type="bibr" rid="bibr18-1066896911429296">18</xref></sup> Based on these backgrounds, we conducted an immunohistochemical study to examine how MUC1 expression is correlated with hypoxic markers (Glut1, Glut3, hexokinase I, HIF-1α, VEGF, and microvessel density [MVD] determinated by CD34), EGFR pathway (EGFR, phosphatase and tensin analogue [PTEN], phospho-Akt, phospho-mTOR, and phospho-S6K), amino acid metabolism (l-type amino acid transporter 1 [LAT1]), and cell cycle regulator (p53) in patients with resected NSCLC.</p>
</sec>
<sec id="section2-1066896911429296" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1066896911429296">
<title>Patients</title>
<p>Between October 2002 and May 2004, 133 consecutive patients with resectable NSCLC underwent curative resection at Shizuoka Cancer Center. Of these, 7 patients were excluded for further studies because the tissue specimens were not available. Thus, a total of 126 patients (81 men, 45 women) were eligible for the study. The study protocol was approved by the institutional review board.</p>
<p>The age of the patients ranged from 40 to 89 years, and the mean age was 66 years. None of the patients had received neoadjuvant chemotherapy. The tumor stage was determined by diagnostic imaging including computed tomography and 2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose positron emission tomography (2-<sup>18</sup>F-FDG PET). All surgical specimens were reviewed and classified according to the World Health Organization classification by an experienced lung pathologist who was unaware of clinical or imaging findings. Pathologic tumor–node–metastasis (TNM) stages were established using the International System for Staging Lung Cancer adopted by the American Joint Committee on Cancer and the Union Internationale Centre le Cancer.<sup><xref ref-type="bibr" rid="bibr19-1066896911429296">19</xref></sup> Histologically, 82 patients had AC, 37 had squamous cell carcinoma (SQC), and 7 had large cell carcinoma. Of the total patients, 63, 25, and 38 had stage I, stage II, and stage III tumors, respectively. As postoperative adjuvant therapies, platinum-based chemotherapy, radiation, and oral administration of tegafur (a fluorouracil-derivative drug) were administered to 9, 1, and 8 patients, respectively. Intraoperative therapy was not performed on any patient. The postoperative clinical course was assessed by analyzing outpatient medical records and by marking telephone inquiries. The day of surgery was considered the starting day for counting postoperative survival. The follow-up duration ranged from 6 to 88 months (median = 62 months).</p>
</sec>
<sec id="section4-1066896911429296">
<title>Immunohistochemical Staining</title>
<p>Immunohistochemical staining was performed according to the procedure described in the previous reports.<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref>,<xref ref-type="bibr" rid="bibr18-1066896911429296">18</xref>,<xref ref-type="bibr" rid="bibr20-1066896911429296">20</xref>,<xref ref-type="bibr" rid="bibr21-1066896911429296">21</xref></sup> The technical details of the antibodies employed in this study are listed in <xref ref-type="table" rid="table1-1066896911429296">Table 1</xref>. LAT1 expression was determined by immunohistochemical staining with an affinity-purified rabbit polyclonal anti-human LAT1 antibody (1.2 mg/mL; 1:3200).<sup><xref ref-type="bibr" rid="bibr22-1066896911429296">22</xref></sup> An oligopeptide corresponding to amino acid residues 497-507 of human LAT1 (CQKLMQVVPQET) was synthesized. The N-terminal cysteine residue was introduced for conjugation with keyhole limpet hemocyanine. Antipeptide antibody was produced as described elsewhere.<sup><xref ref-type="bibr" rid="bibr23-1066896911429296">23</xref></sup> For immunohistochemical analysis, antiserum was affinity purified as described previously.<sup><xref ref-type="bibr" rid="bibr23-1066896911429296">23</xref></sup></p>
<table-wrap id="table1-1066896911429296" position="float">
<label>Table 1.</label>
<caption><p>Technical Details of the Antibodies Employed in this Study</p></caption>
<graphic alternate-form-of="table1-1066896911429296" xlink:href="10.1177_1066896911429296-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Antibody</th>
<th align="center">Clone</th>
<th align="center">Company, City (Country)</th>
<th align="center">Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUC1 (Ma 552)</td>
<td>Rabbit monoclonal</td>
<td>Novocastra Laboratories Ltd, Newcastle (United Kingdom)</td>
<td>1:100</td>
</tr>
<tr>
<td>GLUT1 (AB15309)</td>
<td>Rabbit polyclonal</td>
<td>Abcam, Tokyo (Japan)</td>
<td>1:400</td>
</tr>
<tr>
<td>GLUT3</td>
<td>Rabbit polyclonal</td>
<td>Abcam, Tokyo (Japan)</td>
<td>1:200</td>
</tr>
<tr>
<td>Hexokinase I (AB55144)</td>
<td>Rabbit monoclonal</td>
<td>Abcam, Tokyo (Japan)</td>
<td>1:200</td>
</tr>
<tr>
<td>HIF-1α (NB100-123)</td>
<td>Mouse monoclonal</td>
<td>Novus Biologicals, Oakville, Ontario (Canada)</td>
<td>1:50</td>
</tr>
<tr>
<td>VEGF</td>
<td>Mouse monoclonal</td>
<td>Immuno-Biological Laboratories Co Ltd, Fujioka (Japan)</td>
<td>1:200</td>
</tr>
<tr>
<td>CD34</td>
<td>Mouse monoclonal</td>
<td>Nichirei, Tokyo (Japan)</td>
<td>1:800</td>
</tr>
<tr>
<td>p53 (D07)</td>
<td>Mouse monoclonal</td>
<td>DAKO, Tokyo (Japan)</td>
<td>1:50</td>
</tr>
<tr>
<td>EGFR</td>
<td>Mouse monoclonal</td>
<td>Novocastra Laboratories Ltd, Newcastle (United Kingdom)</td>
<td>1:100</td>
</tr>
<tr>
<td>PTEN</td>
<td>Rabbit monoclonal</td>
<td>Cell Signaling Technology, Inc, Danvers, MA (United States)</td>
<td>1:50</td>
</tr>
<tr>
<td>phosph-AKT</td>
<td>Rabbit polyclonal</td>
<td>Cell Signaling Technology, Inc, Danvers, MA (United States)</td>
<td>1:200</td>
</tr>
<tr>
<td>phosph-mTOR</td>
<td>Rabbit monoclonal</td>
<td>Cell Signaling Technology, Inc, Danvers, MA (United States)</td>
<td>1:80</td>
</tr>
<tr>
<td>phosph-S6K</td>
<td>Rabbit monoclonal</td>
<td>Cell Signaling Technology, Inc, Danvers, MA (United States)</td>
<td>1:100</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896911429296"><p>Abbreviations: Glut1, glucose transporter 1; Glut3, glucose transporter 3; HIF-1α, hypoxia inducible factor-1 alpha; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; PTEN, phosphatase and tensin analogue; mTOR, mammalian target of rapamycin; CD, cluster of differentiation.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>According to previous report,<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref></sup> immunohistochemical analysis of MUC1 expression was evaluated. First, staining density of MUC1 expression was classified into positive or negative, and, if positive, each tumor cell was further classified according to the expression pattern into polarized or depolarized expression. According to the percentage of tumor cells showing polarized MUC1 expression and that with depolarized MUC1 expression, MUC1 expression was classified into the high-grade polarized (HP), the low-grade polarized (LP), or the depolarized (DP) group. The classification of MUC1 expression status is as follows: (a) HP when positive percentage of tumor cells with polarized MUC1 expression is more than 50% and positive percentage of tumor cells with depolarized MUC1 expression is less than 10%, (b) LP when positive percentage of tumor cells with polarized MUC1 expression is less than 50% and positive percentage of tumor cells with depolarized MUC1 expression is less than 10%, and (c) DP when positive percentage of tumor cells with depolarized MUC1 expression is more than 10% regardless of positive percentage with polarized MUC1 expression. According to the definition, the patient with tumor showing no MUC1 expression was classified into the LP group.</p>
<p>The expression of Glut1, Glut3, and EGFR was considered positive if distinct membrane staining was present. Five fields (×400) were analyzed to determine the frequency of the HIF-1α-stained nuclei and hexokinase I–stained cytoplasm. For Glut1, Glut3, EGFR, HIF-1α, and hexokinase I, a semiquantitative scoring method was used as follows: 1 = &lt;10%, 2 = 10% to 25%, 3 = 25% to 50%, 4 = 51% to 75%, and 5 = &gt;75% of cells positive. The tumors in which stained tumor cells made up more than 25% of the tumor were graded as positive. The detailed protocol for immunostaining was published elsewhere.<sup><xref ref-type="bibr" rid="bibr18-1066896911429296">18</xref>,<xref ref-type="bibr" rid="bibr21-1066896911429296">21</xref></sup> LAT1 expression was considered positive only if distinct membrane staining was present. Staining intensity was scored as follows: 1 = ≤10% of tumor area stained, 2 = 11% to 25% stained, 3 = 26% to 50% stained, and 4 = ≥51% stained. The tumors in which stained tumor cells made up more than 10% of the tumor were graded as positive.</p>
<p>The expression of VEGF was quantitatively assessed according to the percentage of immunoreactive cells in the total of 1000 neoplastic cells. The number of CD34-positive vessels was counted in 4 selected hot spots in a ×400 field (0.26 mm<sup>2</sup> field area). MVD was defined as the mean count of microvessels per 0.26 mm<sup>2</sup> field area. For p53, microscopic examination for the nuclear reaction product was performed and scored. p53 expression in more than 10% of tumor cells was defined as high expression. p-AKT, p-mTOR, and p-S6K were considered positive if membranous and/or cytoplasmic staining was present, and PTEN was positive if nuclear staining. For p-AKT, p-mTOR, p-S6K, and PTEN, a semiquantitative scoring method was used: 1 = &lt;10%, 2 = 10% to 25%, 3 = 25% to 50%, 4 = 51% to 75%, and 5 = &gt;75% of cells positive. The tumors in which stained tumor cells made up more than 25% of the tumor were graded as positive. Sections were assessed using light microscopy in a blinded fashion by at least 2 of the authors.</p>
</sec>
<sec id="section5-1066896911429296">
<title>Statistical Analysis</title>
<p>Probability values &lt;.05 indicated a statistically significant difference. Fisher’s exact test was used to examine the association of 2 categorical variables. The Kaplan–Meier method was used to estimate survival as a function of time, and survival difference were analyzed by the log-rank test. Multivariate analyses were performed using stepwise Cox proportional hazards model to identify independent prognostic factors. Statistical analysis was performed using JMP 8 (SAS Institute Inc., Cary, NC) for Windows.</p>
</sec>
</sec>
<sec id="section6-1066896911429296" sec-type="results">
<title>Results</title>
<sec id="section7-1066896911429296">
<title>Immunohistochemical Analysis</title>
<p>Each protein revealed a profile pattern of the unique expression. The immunohistochemical staining of MUC1, Glut1, Glut3, hexokinase I, HIF-1α, VEGF, CD34, LAT1, EGFR, PTEN, p-Akt, p-mTOR, p-S6K, and p53 was evaluated for the 126 primary lesions. <xref ref-type="fig" rid="fig1-1066896911429296">Figure 1</xref> represents the immunohistochemical staining of MUC1 expression. Of all 126 patients, HP, LP, and DP group were 50 (39.7%), 35 (27.8%), and 41 (32.5%), respectively. Glut1 and Glut3 were detected in tumor cells and localized predominantly on their plasma membrane. A positive rate of Glut1 and Glut3 expression was recognized in 67.5% (85/126) and 11.1% (12/126), respectively. A positive expression of HIF-1α was predominantly recognized in the cytoplasm with some nuclear staining and was recognized in 87.3% (101/126). A positive expression of hexokinase I was recognized in the cytoplasm and/or membrane of neoplastic cells and was recognized in 68.3% (86/126). The median rate of VEGF positivity was 35% (range, 3% to 75%), and the value of 35% was chosen as a cutoff point. Positive expression was recognized in 42.9% (54/126). The median numbers of CD34 was 25 (2 to 65), and the value of 25% was chosen as a cutoff point. Positive expression was recognized in 48.4% (61/126). A positive expression of EGFR, PTEN, p-AKT, p-mTOR, p-S6K, and p53 was 55.6% (70/126), 15.1% (19/126), 49.2% (62/126), 60.0% (68/126), and 48.4% (61/126), respectively.</p>
<fig id="fig1-1066896911429296" position="float">
<label>Figure 1.</label>
<caption><p>Immunohistochemical staining of MUC1 in pulmonary adenocarcinoma</p>
<p>A, High-grade polarized expression (HP) pattern of MUC1 in a well-differentiated adenocarcinoma. B, Depolarized expression (DP) pattern of MUC1 in a poorly differentiated adenocarcinoma.</p></caption>
<graphic xlink:href="10.1177_1066896911429296-fig1.tif"/>
</fig>
</sec>
<sec id="section8-1066896911429296">
<title>Demographics of Patients According to MUC1 Expression</title>
<p>The demographic result of the patients according to MUC1 expression is listed in <xref ref-type="table" rid="table2-1066896911429296">Table 2</xref>. The frequency of male, non-AC, vascular invasion, lymphatic permeation, Glut1, HIF-1α, VEGF, MVD, LAT1, EGFR, and loss of PTEN was significantly higher in DP group than in HP group. Non-AC, Glut1, HIF-1α, VEGF, MVD, and LAT1 were significantly higher in DP group than in LP group. Compared with HP group, non-AC, the expression of Glut1, EGFR, loss of PTEN, and p-mTOR was significantly higher in LP group. As lung AC patients were distributed into 3 groups, the analysis of AC patients was further performed (<xref ref-type="table" rid="table3-1066896911429296">Table 3</xref>). The frequency of advanced stage, lymphatic permeation, Glut1, CD34, LAT1, and EGFR was significantly higher in the DP group than in the HP group. MVD yielded a statistically significant difference between the LP and DP groups. Advanced stage and EGFR yielded a statistically significant difference between the HP and LP groups.</p>
<table-wrap id="table2-1066896911429296" position="float">
<label>Table 2.</label>
<caption><p>Different Variables According to MUC1 Expression in All Patients</p></caption>
<graphic alternate-form-of="table2-1066896911429296" xlink:href="10.1177_1066896911429296-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th align="center" colspan="3"><italic>P</italic></th>
</tr>
<tr>
<th align="left" colspan="2">Different Variables</th>
<th align="center">Total (n= 126)</th>
<th align="center">HP (n = 50)</th>
<th align="center">LP (n = 35)</th>
<th align="center">DP (n = 41)</th>
<th align="center">HP/LP</th>
<th align="center">HP/DP</th>
<th align="center">LP/DP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>≤65/&gt;65</td>
<td>56/70</td>
<td>22/28</td>
<td>16/19</td>
<td>18/23</td>
<td>1.000</td>
<td>1.000</td>
<td>1.000</td>
</tr>
<tr>
<td>Gender</td>
<td>Male/female</td>
<td>81/45</td>
<td>26/24</td>
<td>22/13</td>
<td>33/8</td>
<td>.377</td>
<td>.<bold>007</bold></td>
<td>.122</td>
</tr>
<tr>
<td>Histology</td>
<td>AC/non-AC</td>
<td>82/44</td>
<td>47/3</td>
<td>23/12</td>
<td>12/29</td>
<td>.<bold>001</bold></td>
<td><bold>&lt;.001</bold></td>
<td>.<bold>002</bold></td>
</tr>
<tr>
<td>p stage</td>
<td>I + II/III</td>
<td>88/38</td>
<td>38/12</td>
<td>24/11</td>
<td>26/15</td>
<td>.467</td>
<td>.249</td>
<td>.808</td>
</tr>
<tr>
<td>Pl</td>
<td>Positive/negative</td>
<td>34/92</td>
<td>13/37</td>
<td>7/28</td>
<td>14/27</td>
<td>.608</td>
<td>.490</td>
<td>.204</td>
</tr>
<tr>
<td>Vas</td>
<td>Positive/negative</td>
<td>59/67</td>
<td>17/33</td>
<td>16/19</td>
<td>26/15</td>
<td>.366</td>
<td>.<bold>006</bold></td>
<td>.165</td>
</tr>
<tr>
<td>Ly</td>
<td>Positive/negative</td>
<td>58/68</td>
<td>16/34</td>
<td>16/19</td>
<td>26/15</td>
<td>.256</td>
<td>.<bold>003</bold></td>
<td>.165</td>
</tr>
<tr>
<td>LN meta</td>
<td>Positive/negative</td>
<td>50/76</td>
<td>23/27</td>
<td>16/19</td>
<td>11/30</td>
<td>1.000</td>
<td>.081</td>
<td>.098</td>
</tr>
<tr>
<td>Glut1</td>
<td>Positive/negative</td>
<td>85/41</td>
<td>21/29</td>
<td>24/11</td>
<td>40/1</td>
<td>.<bold>026</bold></td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
</tr>
<tr>
<td>Glut3</td>
<td>Positive/negative</td>
<td>14/112</td>
<td>5/45</td>
<td>2/33</td>
<td>7/34</td>
<td>.694</td>
<td>.364</td>
<td>.165</td>
</tr>
<tr>
<td>Hexo I</td>
<td>Positive/negative</td>
<td>86/40</td>
<td>32/18</td>
<td>21/14</td>
<td>33/8</td>
<td>.821</td>
<td>.104</td>
<td>.075</td>
</tr>
<tr>
<td>HIF-1α</td>
<td>Positive/negative</td>
<td>101/25</td>
<td>35/15</td>
<td>27/8</td>
<td>39/2</td>
<td>.620</td>
<td>.<bold>002</bold></td>
<td>.<bold>037</bold></td>
</tr>
<tr>
<td>VEGF</td>
<td>Positive/negative</td>
<td>54/72</td>
<td>16/34</td>
<td>11/24</td>
<td>27/14</td>
<td>1.000</td>
<td>.<bold>001</bold></td>
<td>.<bold>005</bold></td>
</tr>
<tr>
<td>CD34</td>
<td>Positive/negative</td>
<td>61/65</td>
<td>16/34</td>
<td>15/20</td>
<td>30/11</td>
<td>.363</td>
<td><bold>&lt;.001</bold></td>
<td>.<bold>010</bold></td>
</tr>
<tr>
<td>LAT1</td>
<td>Positive/negative</td>
<td>51/75</td>
<td>11/39</td>
<td>10/25</td>
<td>30/11</td>
<td>.610</td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
</tr>
<tr>
<td>EGFR</td>
<td>Positive/negative</td>
<td>70/56</td>
<td>16/34</td>
<td>23/12</td>
<td>31/10</td>
<td>.<bold>003</bold></td>
<td><bold>&lt;.001</bold></td>
<td>.447</td>
</tr>
<tr>
<td>PTEN</td>
<td>Positive/negative</td>
<td>19/107</td>
<td>14/36</td>
<td>2/33</td>
<td>3/38</td>
<td>.<bold>011</bold></td>
<td>.<bold>014</bold></td>
<td>1.000</td>
</tr>
<tr>
<td>p-Akt</td>
<td>Positive/negative</td>
<td>62/64</td>
<td>29/21</td>
<td>18/17</td>
<td>15/20</td>
<td>.658</td>
<td>.191</td>
<td>.632</td>
</tr>
<tr>
<td>p-mTOR</td>
<td>Positive/negative</td>
<td>68/58</td>
<td>32/18</td>
<td>13/22</td>
<td>23/18</td>
<td>.<bold>016</bold></td>
<td>.520</td>
<td>.112</td>
</tr>
<tr>
<td>p-S6K</td>
<td>Positive/negative</td>
<td>86/40</td>
<td>34/16</td>
<td>20/15</td>
<td>32/9</td>
<td>.363</td>
<td>.348</td>
<td>.082</td>
</tr>
<tr>
<td>p53</td>
<td>Positive/negative</td>
<td>61/65</td>
<td>20/30</td>
<td>21/14</td>
<td>20/21</td>
<td>.081</td>
<td>.524</td>
<td>.363</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1066896911429296"><p>NOTE: Boldfaced entries showing statistically significant difference.</p></fn>
<fn id="table-fn3-1066896911429296"><p>Abbreviations: HP, high-grade polarized expression; LP, low-grade polarized expression; DP, depolarized expression; AC, adenocarcinoma; p stage, pathological stage; Pl, pleural involvement; Vas, vascular invasion; Ly, lymphatic permeation; LN meta, lymph node metastasis; Glut1, glucose transporter 1; Glut3, glucose transporter 3; Hexo I, hexokinase I; HIF-1α, hypoxia inducible factor-1 alpha; VEGF, vascular endothelial growth factor; LAT1, l-type amino acid transporter 1; EGFR, epidermal growth factor receptor; PTEN, phosphatase and tensin analog; mTOR, mammalian target of rapamycin; HP/LP, statistical comparison of HP and LP; HP/DP, statistical comparison of HP and DP; DP/LP, statistical comparison of DP and LP.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1066896911429296" position="float">
<label>Table 3.</label>
<caption><p>Different Variables According to MUC1 Expression in Lung Adenocarcinoma</p></caption>
<graphic alternate-form-of="table3-1066896911429296" xlink:href="10.1177_1066896911429296-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th align="center" colspan="3"><italic>P</italic></th>
</tr>
<tr>
<th align="left" colspan="2">Different Variables</th>
<th align="center">Total (n = 82)</th>
<th align="center">HP (n = 47)</th>
<th align="center">LP (n = 23)</th>
<th align="center">DP (n = 12)</th>
<th align="center">HP/LP</th>
<th align="center">HP/DP</th>
<th align="center">LP/DP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>≤65/&gt;65</td>
<td>38/44</td>
<td>20/27</td>
<td>12/11</td>
<td>6/6</td>
<td>.610</td>
<td>.749</td>
<td>1.000</td>
</tr>
<tr>
<td>Gender</td>
<td>Male/female</td>
<td>43/39</td>
<td>23/24</td>
<td>11/12</td>
<td>9/3</td>
<td>1.000</td>
<td>.193</td>
<td>.162</td>
</tr>
<tr>
<td>p stage</td>
<td>I + II/III</td>
<td>54/28</td>
<td>37/10</td>
<td>12/11</td>
<td>5/7</td>
<td>.<bold>029</bold></td>
<td>.<bold>027</bold></td>
<td>.724</td>
</tr>
<tr>
<td>Pl</td>
<td>Positive/negative</td>
<td>21/61</td>
<td>12/35</td>
<td>4/19</td>
<td>5/7</td>
<td>.552</td>
<td>.299</td>
<td>.220</td>
</tr>
<tr>
<td>Vas</td>
<td>Positive/negative</td>
<td>32/50</td>
<td>14/33</td>
<td>10/13</td>
<td>8/4</td>
<td>.291</td>
<td>.041</td>
<td>.289</td>
</tr>
<tr>
<td>Ly</td>
<td>Positive/negative</td>
<td>33/49</td>
<td>14/33</td>
<td>10/13</td>
<td>9/3</td>
<td>.291</td>
<td>.<bold>007</bold></td>
<td>.151</td>
</tr>
<tr>
<td>LN meta</td>
<td>Positive/negative</td>
<td>36/46</td>
<td>21/26</td>
<td>12/11</td>
<td>3/9</td>
<td>.615</td>
<td>.326</td>
<td>.162</td>
</tr>
<tr>
<td>Glut1</td>
<td>Positive/negative</td>
<td>42/40</td>
<td>18/29</td>
<td>13/10</td>
<td>11/1</td>
<td>.201</td>
<td>.<bold>001</bold></td>
<td>.055</td>
</tr>
<tr>
<td>Glut3</td>
<td>Positive/negative</td>
<td>7/75</td>
<td>4/43</td>
<td>1/22</td>
<td>2/10</td>
<td>1.000</td>
<td>.591</td>
<td>.265</td>
</tr>
<tr>
<td>Hexo I</td>
<td>Positive/negative</td>
<td>50/32</td>
<td>29/18</td>
<td>12/11</td>
<td>9/3</td>
<td>.606</td>
<td>.509</td>
<td>.281</td>
</tr>
<tr>
<td>HIF-1α</td>
<td>Positive/negative</td>
<td>60/22</td>
<td>32/15</td>
<td>17/6</td>
<td>11/1</td>
<td>.782</td>
<td>.380</td>
<td>.150</td>
</tr>
<tr>
<td>VEGF</td>
<td>Positive/negative</td>
<td>30/52</td>
<td>16/31</td>
<td>7/16</td>
<td>7/5</td>
<td>1.000</td>
<td>.153</td>
<td>.185</td>
</tr>
<tr>
<td>CD34</td>
<td>Positive/negative</td>
<td>33/49</td>
<td>14/33</td>
<td>9/14</td>
<td>10/2</td>
<td>.588</td>
<td>.<bold>002</bold></td>
<td>.<bold>016</bold></td>
</tr>
<tr>
<td>LAT1</td>
<td>Positive/negative</td>
<td>18/64</td>
<td>8/39</td>
<td>4/19</td>
<td>6/6</td>
<td>1.000</td>
<td>.<bold>026</bold></td>
<td>.059</td>
</tr>
<tr>
<td>EGFR</td>
<td>Positive/negative</td>
<td>39/43</td>
<td>14/33</td>
<td>17/6</td>
<td>8/4</td>
<td><bold>&lt;.001</bold></td>
<td>.<bold>041</bold></td>
<td>.706</td>
</tr>
<tr>
<td>PTEN</td>
<td>Positive/negative</td>
<td>18/64</td>
<td>14/33</td>
<td>3/20</td>
<td>1/11</td>
<td>.149</td>
<td>.160</td>
<td>1.000</td>
</tr>
<tr>
<td>p-Akt</td>
<td>Positive/negative</td>
<td>52/30</td>
<td>27/20</td>
<td>17/6</td>
<td>8/4</td>
<td>.201</td>
<td>.744</td>
<td>.706</td>
</tr>
<tr>
<td>p-mTOR</td>
<td>Positive/negative</td>
<td>46/36</td>
<td>29/18</td>
<td>9/14</td>
<td>8/4</td>
<td>.124</td>
<td>1.000</td>
<td>.164</td>
</tr>
<tr>
<td>p-S6K</td>
<td>Positive/negative</td>
<td>58/24</td>
<td>33/14</td>
<td>15/8</td>
<td>10/2</td>
<td>.785</td>
<td>.482</td>
<td>.434</td>
</tr>
<tr>
<td>p53</td>
<td>Positive/negative</td>
<td>36/46</td>
<td>19/28</td>
<td>13/10</td>
<td>4/8</td>
<td>.307</td>
<td>.749</td>
<td>.289</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1066896911429296"><p>NOTE: Boldfaced entries showing statistically significant difference.</p></fn>
<fn id="table-fn5-1066896911429296"><p>Abbreviations: HP, high-grade polarized expression; LP, low-grade polarized expression; DP, depolarized expression; p stage, pathological stage; Pl, pleural involvement; Vas, vascular invasion; Ly, lymphatic permeation; LN meta, lymph node metastasis; Glut1, glucose transporter 1; Glut3, glucose transporter 3; Hexo I, hexokinase I; HIF-1α, hypoxia inducible factor-1 alpha; VEGF, vascular endothelial growth factor; LAT1, l-type amino acid transporter 1; EGFR, epidermal growth factor receptor; PTEN, Phosphatase and tensin analog; mTOR, mammalian target of rapamycin; HP/LP, statistical comparison of HP and LP; HP/DP, statistical comparison of HP and DP; DP/LP, statistical comparison of DP and LP.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Next, we also performed a quantitative analysis of these molecular markers according to MUC1 expression (<xref ref-type="fig" rid="fig2-1066896911429296">Figure 2</xref>). The mean scoring of Glut1, HIF-1α, LAT1, and EGFR, VEGF positivity, and number of microvessels (CD34), yielded a statistically significant difference among the 3 groups (HP vs LP, HP vs DP, and LP vs DP). All these variables showed a statistically significant difference between HP and DP. The mean scoring of Glut1, HIF-1α, and LAT1, VEGF positivity, and number of microvessels (CD34) showed a statistically significant difference between LP and DP. The mean scoring of Glut1 and EGFR showed a statistically significant difference between HP and LP.</p>
<fig id="fig2-1066896911429296" position="float">
<label>Figure 2.</label>
<caption><p>Quantitative analysis of mean scoring of Glut1, HIF-1α, LAT1 and EGFR, VEGF positivity, and number of microvessels (CD34) according to MUC1 expression</p>
<p>A, Mean scoring of Glut1 showing statistically significant difference between high-grade polarized expression (HP) and low-grade polarized expression (LP), between LP and depolarized expression (DP), and between HP and DP. B, Mean scoring of HIF-1α showing statistically significant difference between HP and DP, and between LP and DP, but not between HP and LP. C, VEGF positivity showing statistically significant difference between HP and DP, and between LP and DP, but not between HP and LP. D, Number of microvessels (CD34) showing statistically significant difference between HP and DP, and between LP and DP, but not between HP and LP. E, Mean scoring of LAT1 showing statistically significant difference between HP and DP, and between LP and DP, but not between HP and LP. F, Mean scoring of EGFR showing statistically significant difference between HP and LP, and between HP and DP, but not between LP and DP. <italic>P</italic> values indicate significance and were calculated using Fisher’s exact test. *<italic>P</italic> &lt; .05, **<italic>P</italic> &lt; .01, ***<italic>P</italic> &lt; .001, NS indicates nonsignificance.</p></caption>
<graphic xlink:href="10.1177_1066896911429296-fig2.tif"/>
</fig>
</sec>
<sec id="section9-1066896911429296">
<title>MUC1 Status and Survival Analysis</title>
<p>For all patients, 5-year survival rates of the HP, LP, and DP patients were 79.4%, 61.5%, and 43.9%, respectively. A statistically significant difference in the overall survival was observed between HP and LP patients (<italic>P</italic> = .0394), and between HP and DP patients (<italic>P</italic> = .0002), demonstrating no significant difference between LP and DP patients (<xref ref-type="fig" rid="fig3-1066896911429296">Figure 3A</xref>). The 5-year survival rates of patients with HP or LP and those with DP were 72.0% and 43.9%, respectively (<italic>P</italic> &lt; .001). The 5-year survival rates according to different variables are listed in <xref ref-type="table" rid="table4-1066896911429296">Table 4</xref>. Univariate analysis demonstrated that male, non-AC, disease stage and the expression of MUC1, Glut1, HIF-1α, VEGF, CD34, LAT1, and EGFR were significantly associated with poor outcome. Multivariate analysis demonstrated that disease stage was an independent prognostic factor for predicting poor outcome.</p>
<fig id="fig3-1066896911429296" position="float">
<label>Figure 3.</label>
<caption><p>High-grade polarized expression (HP), low-grade polarized expression (LP), and depolarized expression (DP)</p>
<p>A, Postoperative survival of non–small cell lung cancer patients according to MUC1 expression pattern. B, Postoperative survival of pulmonary adenocarcinoma patients according to MUC1 expression pattern.</p></caption>
<graphic xlink:href="10.1177_1066896911429296-fig3.tif"/>
</fig>
<table-wrap id="table4-1066896911429296" position="float">
<label>Table 4.</label>
<caption><p>Univariate and Multivariate Survival Analysis in All Patients</p></caption>
<graphic alternate-form-of="table4-1066896911429296" xlink:href="10.1177_1066896911429296-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Univariate Analysis</th>
<th align="center">Multivariate Analysis</th>
</tr>
<tr>
<th align="left" colspan="2">Different Variables</th>
<th align="center">5-Year Survival Rate (%)</th>
<th align="center"><italic>P</italic></th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>≤65/&gt;65</td>
<td>57.6/67.1</td>
<td>.581</td>
<td/>
</tr>
<tr>
<td>Gender</td>
<td>Male/female</td>
<td>55.7/75.4</td>
<td>.<bold>036</bold></td>
<td>.484</td>
</tr>
<tr>
<td>Histology</td>
<td>AC/non-AC</td>
<td>70.2/48.9</td>
<td>.<bold>011</bold></td>
<td>.328</td>
</tr>
<tr>
<td>p stage</td>
<td>I + II/III</td>
<td>71.4/40.9</td>
<td><bold>&lt;.001</bold></td>
<td>.<bold>007</bold></td>
</tr>
<tr>
<td>MUC1</td>
<td>HP/LP and DP</td>
<td>72.0/43.9</td>
<td><bold>&lt;.001</bold></td>
<td>.839</td>
</tr>
<tr>
<td>Glut1</td>
<td>Positive/negative</td>
<td>49.5/89.9</td>
<td><bold>&lt;.001</bold></td>
<td>.<bold>004</bold></td>
</tr>
<tr>
<td>Glut3</td>
<td>Positive/negative</td>
<td>59.6/62.0</td>
<td>.558</td>
<td/>
</tr>
<tr>
<td>Hexo I</td>
<td>Positive/negative</td>
<td>60.7/67.3</td>
<td>.474</td>
<td/>
</tr>
<tr>
<td>HIF-1α</td>
<td>Positive/negative</td>
<td>56.4/88.0</td>
<td>.<bold>011</bold></td>
<td>.379</td>
</tr>
<tr>
<td>VEGF</td>
<td>Positive/negative</td>
<td>52.5/70.8</td>
<td><bold>&lt;.001</bold></td>
<td>.956</td>
</tr>
<tr>
<td>CD34</td>
<td>Positive/negative</td>
<td>48.5/76.2</td>
<td><bold>&lt;.001</bold></td>
<td>.554</td>
</tr>
<tr>
<td>LAT1</td>
<td>Positive/negative</td>
<td>57.6/74.1</td>
<td>.<bold>038</bold></td>
<td>.618</td>
</tr>
<tr>
<td>EGFR</td>
<td>Positive/negative</td>
<td>49.1/79.9</td>
<td>.<bold>005</bold></td>
<td>.235</td>
</tr>
<tr>
<td>PTEN</td>
<td>Positive/negative</td>
<td>82.6/59.4</td>
<td>.076</td>
<td/>
</tr>
<tr>
<td>p-Akt</td>
<td>Positive/negative</td>
<td>62.5/63.2</td>
<td>.818</td>
<td/>
</tr>
<tr>
<td>p-mTOR</td>
<td>Positive/negative</td>
<td>66.5/58.6</td>
<td>.542</td>
<td/>
</tr>
<tr>
<td>p-S6K</td>
<td>Positive/negative</td>
<td>52.8/69.9</td>
<td>.098</td>
<td/>
</tr>
<tr>
<td>p53</td>
<td>Positive/negative</td>
<td>61.7/63.7</td>
<td>.953</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1066896911429296"><p>NOTE: Boldfaced entries showing statistically significant difference.</p></fn>
<fn id="table-fn7-1066896911429296"><p>Abbreviations: HP, high-grade polarized expression; LP, low-grade polarized expression; DP, depolarized expression; AC, adenocarcinoma; p stage, pathological stage; Pl, pleural involvement; Vas, vascular invasion; Ly, lymphatic permeation; LN meta, lymph node metastasis; Glut1, glucose transporter 1; Glut3, glucose transporter 3; Hexo I, hexokinase I; HIF-1α, hypoxia inducible factor-1 alpha; VEGF, vascular endothelial growth factor; LAT1, l-type amino acid transporter 1; EGFR, epidermal growth factor receptor; PTEN, phosphatase and tensin analog; mTOR, mammalian target of rapamycin; HP/LP, statistical comparison of HP and LP; HP/DP, statistical comparison of HP and DP; DP/LP, statistical comparison of DP and LP.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>For AC patients, 5-year survival rates of the HP, LP, and DP patients were 84.5%, 56.5%, and 33.3%, respectively. A statistically significant difference in the overall survival was recognized between HP and LP patients (<italic>P</italic> = .0263), between LP and DP patients (<italic>P</italic> = .0454), and between HP and DP patients (<italic>P</italic> &lt; .0001). The 5-year survival rates of patients with HP or LP and those with DP were 76.7% and 33.3%, respectively (<italic>P</italic> &lt; .001). The 5-year survival rates according to different variables are listed in <xref ref-type="table" rid="table5-1066896911429296">Table 5</xref>. Univariate analysis demonstrated that disease stage and the expression of MUC1, Glut1, HIF-1α, VEGF, CD34, LAT1, and EGFR were significantly associated with poor outcome. By multivariate analysis, there was no statistically significant independent prognostic factor.</p>
<table-wrap id="table5-1066896911429296" position="float">
<label>Table 5.</label>
<caption><p>Univariate and Multivariate Survival Analysis in Adenocarcinoma</p></caption>
<graphic alternate-form-of="table5-1066896911429296" xlink:href="10.1177_1066896911429296-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Univariate Analysis</th>
<th align="center">Multivariate Analysis</th>
</tr>
<tr>
<th align="left" colspan="2">Different Variables</th>
<th align="center">5-Year Survival Rate (%)</th>
<th align="center"><italic>P</italic></th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>≤65/&gt;65 years</td>
<td>64.6/75.7</td>
<td>.586</td>
<td/>
</tr>
<tr>
<td>Gender</td>
<td>Male/female</td>
<td>64.4/76.7</td>
<td>.158</td>
<td/>
</tr>
<tr>
<td>p stage</td>
<td>I + II/III</td>
<td>80.0/48.2</td>
<td>.<bold>002</bold></td>
<td>.524</td>
</tr>
<tr>
<td>MUC1</td>
<td>HP/LP and DP</td>
<td>76.7/33.3</td>
<td><bold>&lt;.001</bold></td>
<td>.269</td>
</tr>
<tr>
<td>Glut1</td>
<td>Positive/negative</td>
<td>51.4/89.6</td>
<td><bold>&lt;.001</bold></td>
<td>.<bold>021</bold></td>
</tr>
<tr>
<td>Glut3</td>
<td>Positive/negative</td>
<td>64.2/68.7</td>
<td>.972</td>
<td/>
</tr>
<tr>
<td>Hexo I</td>
<td>Positive/negative</td>
<td>67.0/75.0</td>
<td>.253</td>
<td/>
</tr>
<tr>
<td>HIF-1α</td>
<td>Positive/negative</td>
<td>62.4/90.9</td>
<td>.<bold>017</bold></td>
<td>.821</td>
</tr>
<tr>
<td>VEGF</td>
<td>Positive/negative</td>
<td>52.7/80.3</td>
<td><bold>&lt;.001</bold></td>
<td>.931</td>
</tr>
<tr>
<td>CD34</td>
<td>Positive/negative</td>
<td>43.5/87.7</td>
<td><bold>&lt;.001</bold></td>
<td>.089</td>
</tr>
<tr>
<td>LAT1</td>
<td>Positive/negative</td>
<td>62.9/87.5</td>
<td>.<bold>012</bold></td>
<td>.380</td>
</tr>
<tr>
<td>EGFR</td>
<td>Positive/negative</td>
<td>55.1/83.6</td>
<td>.<bold>016</bold></td>
<td>.413</td>
</tr>
<tr>
<td>PTEN</td>
<td>Positive/negative</td>
<td>82.6/66.6</td>
<td>.220</td>
<td/>
</tr>
<tr>
<td>p-Akt</td>
<td>Positive/negative</td>
<td>66.8/76.2</td>
<td>.125</td>
<td/>
</tr>
<tr>
<td>p-mTOR</td>
<td>Positive/negative</td>
<td>67.9/72.9</td>
<td>.400</td>
<td/>
</tr>
<tr>
<td>p-S6K</td>
<td>Positive/negative</td>
<td>52.1/75.9</td>
<td>.152</td>
<td/>
</tr>
<tr>
<td>p53</td>
<td>Positive/negative</td>
<td>63.0 / 75.6</td>
<td>.204</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-1066896911429296"><p>NOTE: Boldfaced entries showing statistically significant difference.</p></fn>
<fn id="table-fn9-1066896911429296"><p>Abbreviations: HP, high-grade polarized expression; LP, low-grade polarized expression; DP, depolarized expression; p stage, pathological stage; Pl, pleural involvement; Vas, vascular invasion; Ly, lymphatic permeation; LN meta, lymph node metastasis; Glut1, glucose transporter 1; Glut3, glucose transporter 3; Hexo I, hexokinase I; HIF-1α, hypoxia inducible factor-1 alpha; VEGF, vascular endothelial growth factor; LAT1, l-type amino acid transporter 1; EGFR, epidermal growth factor receptor; PTEN, phosphatase and tensin analog; mTOR, mammalian target of rapamycin; HP/LP, statistical comparison of HP and LP; HP/DP, statistical comparison of HP and DP; DP/LP, statistical comparison of DP and LP.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>For non-AC patients, the 5-year survival rates of patients with HP or LP and those with DP were 50.0% and 44.8%, respectively, demonstrating no significant difference (<italic>P</italic> = .8821).</p>
</sec>
</sec>
<sec id="section10-1066896911429296" sec-type="discussion">
<title>Discussion</title>
<p>This is a retrospective study to evaluate the relationship between MUC1 expression and various molecular markers in patients with resected NSCLC. Depolarized MUC1 expression was significantly related to poor outcome and was closely associated with glucose metabolism (Glut1), hypoxia (HIF-1α), angiogenesis (VEGF and MVD), amino acid metabolism (LAT1), and EGFR expression (<xref ref-type="fig" rid="fig4-1066896911429296">Figure 4</xref>). High-grade polarized MUC1 expression was associated with favorable prognosis and AC. The expression of hypoxic markers, LAT1, and EGFR was significantly lower in HP patients than in DP patients. In AC patients, glucose metabolism, MVD, amino acid metabolism, and EGFR yielded a statistically significant difference between HP and DP patients. Our results suggest that glucose and amino acid metabolism, hypoxia, angiogenesis, and EGFR expression have a crucial role in the development of cancer progression and metastases in NSCLC patients with depolarized MUC1 expression. In the clinicopathological study using tumor specimens, to our knowledge, there is still no data about the relationship between MUC1 expression and these biomarkers in human neoplasms.</p>
<fig id="fig4-1066896911429296" position="float">
<label>Figure 4.</label>
<caption><p>MUC1 expression is significantly associated with the expression of glucose metabolism (Glut1), hypoxia (HIF-1α), angiogenesis (VEGF and CD34), amino acid metabolism (LAT1), and EGFR. HIF-1α is a downstream component of EGFR pathway, and the expression of Glut1 and VEGF is regulated by hypoxia (HIF-1α) in a HIF-1-dependent way</p></caption>
<graphic xlink:href="10.1177_1066896911429296-fig4.tif"/>
</fig>
<p>Recently, several reports have documented that MUC1 expression is correlated with tumor differentiation and postoperative survival in patients with NSCLC.<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref>,<xref ref-type="bibr" rid="bibr7-1066896911429296">7</xref><xref ref-type="bibr" rid="bibr8-1066896911429296"/><xref ref-type="bibr" rid="bibr9-1066896911429296"/>-<xref ref-type="bibr" rid="bibr10-1066896911429296">10</xref></sup> Nagai et al<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref></sup> described that depolarized MUC1 expression was a significant and independent prognostic factor to predict poor postoperative prognosis in patients with pulmonary AC and LP or DP expression was mostly observed in moderately to poorly differentiated AC patients. Situ et al<sup><xref ref-type="bibr" rid="bibr10-1066896911429296">10</xref></sup> also reported that MUC1 has a prognostic relevance in early-stage lung AC. This is corresponding to the results of our study. However, 2 studies reported that MUC1 expression was correlated with worse prognosis not AC but SQC, demonstrating a contradictory result.<sup><xref ref-type="bibr" rid="bibr5-1066896911429296">5</xref>,<xref ref-type="bibr" rid="bibr7-1066896911429296">7</xref></sup> The other reports demonstrated that MUC1 status alone was not correlated to survival in lung cancer.<sup><xref ref-type="bibr" rid="bibr24-1066896911429296">24</xref>,<xref ref-type="bibr" rid="bibr25-1066896911429296">25</xref></sup> Therefore, Nagai et al<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref></sup> conducted a more detailed MUC1 status classification (HP, LP, and DP) and showed a significant difference in postoperative survival between HP and DP. Although the expression profile of MUC1 is different among the studies and the methods used in the studies also have a different technique, we selected the expression analysis of MUC1 according to the study by Nagai et al.<sup><xref ref-type="bibr" rid="bibr3-1066896911429296">3</xref></sup> To assume prospective validation, these molecular techniques will need optimization and standardization in further trials.</p>
<p>In the present study, the expression profile of molecular markers was markedly different between HP and DP groups. Kikami et al<sup><xref ref-type="bibr" rid="bibr11-1066896911429296">11</xref></sup> suggest that hypoxia enhances MUC1 expression in lung AC cell line. As this is an in vitro study, it remains unknown whether hypoxia strongly enhanced depolarized MUC1 expression as compared with polarized MUC expression. However, our results suggest that the degree of hypoxia was higher in the tumors with depolarized MUC1 expression than in those with polarized MUC1 expression, and HIF-1α is upregulated by hypoxia and induces Glut1 expression and angiogenesis. Moreover, the activation of EGFR pathway and amino acid transporter (LAT1) also may play a crucial role in the tumor progression and metastases. This is also supported by the findings that MUC1 expression was found in highly vascularized tumors, a significant coexpression with multiple angiogenic factors and their receptors.<sup><xref ref-type="bibr" rid="bibr9-1066896911429296">9</xref></sup> Moreover, one experimental study demonstrated that suppression of MUC1 synthesis downregulates expression of EGFR at both the mRNA and protein level in human carcinoma cells.<sup><xref ref-type="bibr" rid="bibr26-1066896911429296">26</xref></sup> However, our study indicated that the prognostic role of MUC1 expression seemed to be weak as compared with that of Glut1 expression. As the sample size is small, further investigation is warranted.</p>
<p>Nowadays, the development of immunotherapy is important as new option for cancer therapy. MUC1 core protein may be a useful target molecule for immunotherapy in breast cancer, lung cancer, and other malignancies expressing MUC1.<sup><xref ref-type="bibr" rid="bibr27-1066896911429296">27</xref>,<xref ref-type="bibr" rid="bibr28-1066896911429296">28</xref></sup> Most patients with NSCLC had a positive expression of MUC1, therefore a MUC1-targeted immunotherapy may be appropriate for NSCLC showing MUC1 expression. Especially, the MUC1-targeted therapy will be expected to be administered for NSCLC with depolarized MUC1 expression showing poor outcome. Moreover, MUC1 expression is correlated with hypoxia and Glut1 expression. 2-<sup>18</sup>F-FDG PET has been investigated for monitoring tumor response to chemotherapy, radiotherapy, and molecular targeted therapy.<sup><xref ref-type="bibr" rid="bibr29-1066896911429296">29</xref>,<xref ref-type="bibr" rid="bibr30-1066896911429296">30</xref></sup> The amount of <sup>18</sup>F-FDG uptake in human neoplasm is determined by the presence of glucose metabolism (Glut1), hypoxia (HIF-1α), and angiogenesis (VEGF and MVD).<sup><xref ref-type="bibr" rid="bibr20-1066896911429296">20</xref></sup> Thus, <sup>18</sup>F-FDG PET may be useful for monitoring the response of NSCLC treated by MUC1-targeted therapy. Moreover, <sup>18</sup>F-FDG PET may be effective for differentiating between polarized MUC1 and depolarized MUC1 expression tumors.</p>
<p>In conclusion, depolarized MUC1 expression was significantly associated with poor outcome in NSCLC, especially in lung AC. Glucose metabolism (Glut1), hypoxia (HIF-1α), angiogenesis (VEGF and MVD), amino acid metabolism (LAT1), and EGFR expression have a crucial role in the development of depolarized MUC1 expression. A novel classification of MUC1 expression pattern (HP, LP, and DP) may be useful for predicting postoperative outcome in NSCLC, especially in pulmonary AC.</p>
</sec>
</body>
<back>
<ack><p>We thank the staff of pathology department in Shizuoka Cancer Center for their technical assistance of immunohistochemical analysis.</p></ack>
<fn-group>
<fn fn-type="conflict"><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn>
<fn fn-type="financial-disclosure"><p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article:This work was supported in part by Grant No. 21790793 (KK) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and National Hospital Organization Policy Based Medical Services.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896911429296">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gendler</surname><given-names>SJ</given-names></name>
<name><surname>Lancaster</surname><given-names>CA</given-names></name>
<name><surname>Taylor-Papadimitriou</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin</article-title>. <source>J Biol Chem</source>. <year>1990</year>;<volume>265</volume>: <fpage>15286</fpage>-<lpage>15293</lpage>.</citation>
</ref>
<ref id="bibr2-1066896911429296">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schroeder</surname><given-names>JA</given-names></name>
<name><surname>Masril</surname><given-names>AA</given-names></name>
<name><surname>Adriance</surname><given-names>MC</given-names></name><etal/>
</person-group>. <article-title>MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation</article-title>. <source>Oncogene</source>. <year>2004</year>;<volume>23</volume>: <fpage>5739</fpage>-<lpage>5747</lpage>.</citation>
</ref>
<ref id="bibr3-1066896911429296">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagai</surname><given-names>S</given-names></name>
<name><surname>Takenaka</surname><given-names>K</given-names></name>
<name><surname>Sonobe</surname><given-names>M</given-names></name>
<name><surname>Ogawa</surname><given-names>E</given-names></name>
<name><surname>Wada</surname><given-names>H</given-names></name>
<name><surname>Tanaka</surname><given-names>F</given-names></name>
</person-group>. <article-title>A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer</article-title>. <source>J Thorac Oncol</source>. <year>2006</year>;<volume>1</volume>:<fpage>46</fpage>-<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr4-1066896911429296">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broadbent</surname><given-names>R</given-names></name>
<name><surname>Thynne</surname><given-names>G</given-names></name>
<name><surname>McKenzie</surname><given-names>IFC</given-names></name>
</person-group>. <article-title>Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein</article-title>. <source>J Clin Invest</source>. <year>1997</year>;<volume>100</volume>:<fpage>2783</fpage>-<lpage>2792</lpage>.</citation>
</ref>
<ref id="bibr5-1066896911429296">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woenckhaus</surname><given-names>M</given-names></name>
<name><surname>Merk</surname><given-names>J</given-names></name>
<name><surname>Stoehr</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer</article-title>. <source>Hum Pathol</source>. <year>2008</year>;<volume>39</volume>:<fpage>126</fpage>-<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr6-1066896911429296">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brundage</surname><given-names>MD</given-names></name>
<name><surname>Davies</surname><given-names>D</given-names></name>
<name><surname>Mackillop</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Prognostic factors in non-small cell lung cancer: a decade of prognosis</article-title>. <source>Chest</source>. <year>2002</year>;<volume>122</volume>:<fpage>1037</fpage>-<lpage>1057</lpage>.</citation>
</ref>
<ref id="bibr7-1066896911429296">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guddo</surname><given-names>F</given-names></name>
<name><surname>Giatromanoiaki</surname><given-names>A</given-names></name>
<name><surname>Koukourakis</surname><given-names>MI</given-names></name>
<etal/>
</person-group>. <article-title>MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erb B-2 expression and correlates with poor survival in node positive patients</article-title>. <source>J Clin Pathol</source>. <year>2008</year>;<volume>51</volume>:<fpage>667</fpage>-<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr8-1066896911429296">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirasawa</surname><given-names>Y</given-names></name>
<name><surname>Kohno</surname><given-names>N</given-names></name>
<name><surname>Yokoyama</surname><given-names>A</given-names></name>
<name><surname>Kondo</surname><given-names>K</given-names></name>
<name><surname>Hiwada</surname><given-names>K</given-names></name>
<name><surname>Miyake</surname><given-names>M</given-names></name>
</person-group>. <article-title>Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2000</year>;<volume>16</volume>:<fpage>589</fpage>-<lpage>594</lpage>.</citation>
</ref>
<ref id="bibr9-1066896911429296">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giatromanolaki</surname><given-names>A</given-names></name>
<name><surname>Koukourakis</surname><given-names>MI</given-names></name>
<name><surname>Sivridis</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways</article-title>. <source>Clin Cancer Res</source>. <year>2000</year>;<volume>6</volume>:<fpage>1917</fpage>-<lpage>1921</lpage>.</citation>
</ref>
<ref id="bibr10-1066896911429296">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Situ</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Ma</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer [published online ahead of print November 30, 2010]</article-title>. <source>Med Oncol</source>. doi:10.1007/s12032-010-9752-4<pub-id pub-id-type="doi">10.1007/s12032-010-9752-4</pub-id></citation>
</ref>
<ref id="bibr11-1066896911429296">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kikami</surname><given-names>Y</given-names></name>
<name><surname>Hisatsune</surname><given-names>A</given-names></name>
<name><surname>Tashiro</surname><given-names>T</given-names></name>
<name><surname>Isohama</surname><given-names>Y</given-names></name>
<name><surname>Katsuki</surname><given-names>H</given-names></name>
</person-group>. <article-title>Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2009</year>;<volume>379</volume>: <fpage>1060</fpage>-<lpage>1065</lpage>.</citation>
</ref>
<ref id="bibr12-1066896911429296">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryan</surname><given-names>HE</given-names></name>
<name><surname>Polni</surname><given-names>M</given-names></name>
<name><surname>McNulty</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Hypoxia-inducible factor-1α is a positive factor in solid tumor growth</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>:<fpage>4010</fpage>-<lpage>4015</lpage>.</citation>
</ref>
<ref id="bibr13-1066896911429296">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vleugel</surname><given-names>MM</given-names></name>
<name><surname>Greijer</surname><given-names>AE</given-names></name>
<name><surname>Shvarts</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer</article-title>. <source>J Clin Pathol</source>. <year>2005</year>;<volume>58</volume>:<fpage>172</fpage>-<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr14-1066896911429296">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elson</surname><given-names>DA</given-names></name>
<name><surname>Ryan</surname><given-names>HE</given-names></name>
<name><surname>Snow</surname><given-names>JW</given-names></name>
<name><surname>Johnson</surname><given-names>R</given-names></name>
<name><surname>Arbeit</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Coordinate up-regulation of hypoxia inducible factor (HIF)-1a and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing 1</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>:<fpage>6189</fpage>-<lpage>6195</lpage>.</citation>
</ref>
<ref id="bibr15-1066896911429296">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hisatsune</surname><given-names>A</given-names></name>
<name><surname>Nakayama</surname><given-names>H</given-names></name>
<name><surname>Kawasaki</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2011</year>;<volume>405</volume>:<fpage>377</fpage>-<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr16-1066896911429296">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raina</surname><given-names>D</given-names></name>
<name><surname>Kharbanda</surname><given-names>S</given-names></name>
<name><surname>Kufe</surname><given-names>D</given-names></name>
</person-group>. <article-title>The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts</article-title>. <source>J Biol Chem</source>. <year>1994</year>;<volume>279</volume>:<fpage>20607</fpage>-<lpage>20612</lpage>.</citation>
</ref>
<ref id="bibr17-1066896911429296">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaira</surname><given-names>K</given-names></name>
<name><surname>Yamamoto</surname><given-names>N</given-names></name>
</person-group>. <article-title>Prognostic and predictive factors in resected non-small cell lung cancer</article-title>. <source>Expert Opin Med Diagn</source>. <year>2010</year>;<volume>4</volume>:<fpage>373</fpage>-<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr18-1066896911429296">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaira</surname><given-names>K</given-names></name>
<name><surname>Oriuchi</surname><given-names>N</given-names></name>
<name><surname>Imai</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic significance of l-type amino acid transporter 1 expression in resectable stage l-III nonsmall cell lung cancer</article-title>. <source>Br J Cancer</source>. <year>2008</year>;<volume>98</volume>:<fpage>742</fpage>-<lpage>748</lpage>.</citation>
</ref>
<ref id="bibr19-1066896911429296">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mountain</surname><given-names>CF</given-names></name>
</person-group>. <article-title>Revision in the international system for staging lung cancer</article-title>. <source>Chest</source>. <year>1997</year>;<volume>11</volume>:<fpage>1710</fpage>-<lpage>1717</lpage>.</citation>
</ref>
<ref id="bibr20-1066896911429296">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaira</surname><given-names>K</given-names></name>
<name><surname>Endo</surname><given-names>M</given-names></name>
<name><surname>Abe</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Biologic correlation of 2-[<sup>18</sup>F-]fluoro-2-deoxy-d-glucose uptake on positron emission tomography in thymic epithelial tumors</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>3746</fpage>-<lpage>3753</lpage>.</citation>
</ref>
<ref id="bibr21-1066896911429296">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaira</surname><given-names>K</given-names></name>
<name><surname>Oriuchi</surname><given-names>N</given-names></name>
<name><surname>Shimizu</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Correlation of angiogenesis with <sup>18</sup>F-FMT and <sup>18</sup>F-FDG uptake in non-small cell lung cancer</article-title>. <source>Cancer Sci</source>. <year>2009</year>;<volume>100</volume>:<fpage>753</fpage>-<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr22-1066896911429296">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nawashiro</surname><given-names>H</given-names></name>
<name><surname>Otani</surname><given-names>N</given-names></name>
<name><surname>Shinomiya</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>l-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors</article-title>. <source>Int J Cancer</source>. <year>2006</year>;<volume>119</volume>:<fpage>484</fpage>-<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr23-1066896911429296">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chairoungdua</surname><given-names>A</given-names></name>
<name><surname>Segawa</surname><given-names>H</given-names></name>
<name><surname>Kim</surname><given-names>JY</given-names></name>
<etal/>
</person-group>. <article-title>Identification of an amino acid transporter associated with the cystinuria- related type II membrane glycoprotein</article-title>. <source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>: <fpage>28845</fpage>-<lpage>28848</lpage>.</citation>
</ref>
<ref id="bibr24-1066896911429296">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsutsumida</surname><given-names>H</given-names></name>
<name><surname>Goto</surname><given-names>M</given-names></name>
<name><surname>Kitajima</surname><given-names>S</given-names></name>
<name><surname>Kubota</surname><given-names>I</given-names></name>
<name><surname>Hirotsu</surname><given-names>Y</given-names></name>
<name><surname>Yonezawa</surname><given-names>S</given-names></name>
</person-group>. <article-title>Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma</article-title>. <source>Histopathology</source>. <year>2004</year>;<volume>44</volume>:<fpage>147</fpage>-<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr25-1066896911429296">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarrard</surname><given-names>LA</given-names></name>
<name><surname>Linnoila</surname><given-names>RL</given-names></name>
<name><surname>Lee</surname><given-names>H</given-names></name>
<name><surname>Steinberg</surname><given-names>SM</given-names></name>
<name><surname>Witschi</surname><given-names>H</given-names></name>
<name><surname>Szabo</surname><given-names>E</given-names></name>
</person-group>. <article-title>MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis</article-title>. <source>Cancer Res</source>. <year>1998</year>;<volume>58</volume>: <fpage>5582</fpage>-<lpage>5589</lpage>.</citation>
</ref>
<ref id="bibr26-1066896911429296">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Nunes</surname><given-names>DP</given-names></name>
<name><surname>Troxler</surname><given-names>RF</given-names></name>
<name><surname>Offner</surname><given-names>GD</given-names></name>
</person-group>. <article-title>Suppression of MUC1 synthesis downregulates expression of the epidermal growth factor receptor</article-title>. <source>Cancer Biol Ther</source>. <year>2005</year>;<volume>4</volume>:<fpage>968</fpage>-<lpage>973</lpage>.</citation>
</ref>
<ref id="bibr27-1066896911429296">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kontani</surname><given-names>K</given-names></name>
<name><surname>Taguchi</surname><given-names>O</given-names></name>
<name><surname>Ozaki</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucins</article-title>. <source>Int J Mol Med</source>. <year>2003</year>;<volume>12</volume>:<fpage>493</fpage>-<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr28-1066896911429296">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kufe</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Functional targeting of MUC1 oncogene in human cancers</article-title>. <source>Cancer Biol Ther</source>. <year>2009</year>;<volume>8</volume>:<fpage>1197</fpage>-<lpage>1203</lpage>.</citation>
</ref>
<ref id="bibr29-1066896911429296">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pöttgen</surname><given-names>C</given-names></name>
<name><surname>Levegrün</surname><given-names>S</given-names></name>
<name><surname>Theegarten</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Value of <sup>18</sup>F-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy</article-title>. <source>Clin Cancer Res</source>. <year>2006</year>;<volume>12</volume>:<fpage>97</fpage>-<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr30-1066896911429296">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sunaga</surname><given-names>N</given-names></name>
<name><surname>Oriuchi</surname><given-names>N</given-names></name>
<name><surname>Kaira</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer</article-title>. <source>Lung Cancer</source>. <year>2008</year>;<volume>59</volume>:<fpage>203</fpage>-<lpage>210</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>